Making or Losing Money with Participation in Clinical Trials: A Decision Analysis

Abstract

Background: There is increasing demand and qualitydriven pressure from professional organizations for physicians and health care providers to increase participation in clinical studies. But this can have a severe financial impact on the institution, so costs should be identified and calculated in advance. Method: In a diagram, the decisionmaking process to participate in clinical trials based on economic and budget impact is reviewed and analyzed in detail. Results: This flow chart describes how costeffective participation in clinical trials is determined. Since its implementation, all trials in our institution have been cost covering. Conclusions: All service and care required within the studies must be distinguished as either medically necessary or study related. Costs for the first category have to be covered by the health care system, but in case of the second category by the study sponsor. The institution’s own costs for studyrelated services should be known and deducted from the study income to determine the actual study gains. Subsidizing studies from tight clinic budgets is difficult in times of rationed medicine and should be avoided. Noncostcovering clinical studies should be renegotiated with the sponsor until cost effectiveness is reached. Otherwise, a rejection of study participation for financial reasons should be seriously considered. The design of costcovering clinical trials supports better recruitment for studies.

Relevance of Health Economics in Breast Cancer Treatment: Integration of Economics in the Management of Breast Cancer at the Clinic Level

“…Based on and derived from this information, cost drivers can preferably be identified, and a cautious and gentile long-term optimization process can be induced towards a care-to-reimbursement adjustment. Over the years a variety of successful projects have evolved among them; optimizing chemotherapy reimbursement with reduction of oncological pharmaceutical costs by over 83% in just 2 years without changing quality of care [26,27,28], comparison of different chemoregimen [29], process analysis to discover mistakes in ordering, cost attribution, documentation, coding and billing for out-patient chemotherapies [30], prospective analysis of cost and reimbursement for participation in clinical trials [31], identification of off-label status for pharmaceuticals which are not reimbursed by statutory healthcare funds [32], analysis of costs and financial risks of expensive breast implants at 90% under-reimbursed in immediate breast reconstruction after mastectomy [33], prospective study of provider's costs of chemotherapy-related complications such as febrile neutropenia [34] and analysis and optimization of their correlating DRG reimbursement [35], prospective calculation of direct medication cost savings by biomarkers for avoiding chemotherapy in breast cancer at medium relapse risk [36], purchase and contract adjustments for reduction of costs of expensive breast ultrasound equipment to actual clinical needs [37], and identifying unexplainable reimbursement differences of mastectomy between prophylactic BRCA1/BRCA2 and breast cancer patients [38]. Even concordance of biomarker test results to Tumor Board decisions and final therapy can result in economic effects which can be used to optimize cost for their application [39].…”

Aufgaben und Funktion eines Abrechnungsexperten in einer Frauenklinik

“…Erst eine prospektive Kalkulation der eigenen Kosten für die im Studienprotokoll geforderten Leistungen und der Abgleich mit den auf Drittmittelkonten verbuchten Erlösen und ggf. eine Nachverhandlung bei nachgewiesener Untervergütung können sicherstellen, dass eine Studienteilnahme kostendeckend ist [7]. Dabei können die Kostenunterschiede zwischen experimentellem und Standardarm stark divergieren [1].…”

Financial Quality Control of In-Patient Chemotherapy in Germany: Are Additional Payments Cost-Covering for Pharmaco-Oncological Expenses?

“…The increasing cost awareness within German hospitals due to the German flat rate DRG reimbursement system requires a full understanding and active cost management for highly expensive material expenses like for oncological medications [2][3][4], especially within clinical trials [5,6]. Hospital costs have to be determined and compared to entity-related revenues in order to provide cost-covering care [7,8].…”